Cognitive Peptides: Semax, Selank, and the Science of Nootropic Research

Peptide Portal ResearchEditorial Team

·May 10, 2026·18 min read

Semax and Selank are synthetic peptides developed in Russia during the 1980s that target the brain's neurotrophic and GABAergic systems. Both have been prescription medications in Russia for over a decade: Semax for stroke recovery and cognitive impairment, Selank for generalized anxiety disorder. Their mechanisms center on upregulating brain-derived neurotrophic factor (BDNF), a protein essential for memory formation and neuronal plasticity. While neither peptide is FDA-approved in the United States, Semax will appear before the FDA's Pharmacy Compounding Advisory Committee in July 2026 for potential inclusion on the 503A Bulks List.

This article examines the published research on these cognitive peptides, their mechanisms, clinical applications in Russian medicine, emerging Alzheimer's research, and the current US regulatory landscape.

This content is for informational purposes only and does not constitute medical advice. Consult a healthcare provider before using any peptides.

What Is Semax and How Does It Work?

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of adrenocorticotropic hormone (ACTH) fragment 4-10. Russian researchers at the Institute of Molecular Genetics developed the compound in the 1980s, and it has been listed on Russia's registry of Vital and Essential Drugs since 2011.

The primary mechanism involves rapid upregulation of BDNF, the neurotrophic factor most directly associated with learning and memory consolidation. According to research published in PubMed, a single intranasal dose of Semax at 50 mcg/kg produced the following effects in rat brain tissue:

BDNF protein increased 1.4-fold
BDNF mRNA expression increased 3-fold
TrkB receptor phosphorylation increased 1.6-fold

These changes occurred within 90 minutes of administration and persisted for several hours. The TrkB receptor is BDNF's primary signaling partner, and its phosphorylation activates downstream pathways including PI3K/Akt and Ras/MAPK/ERK, both of which promote synaptic protein synthesis and dendritic growth.

Beyond BDNF, Semax modulates dopaminergic and serotonergic neurotransmission. This positions it as a peptide with effects on both cognition and mood regulation, though the clinical implications of these additional pathways remain less well-characterized.

What Is Selank and What Makes It Different?

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived from tuftsin, an endogenous immunomodulatory tetrapeptide. The Institute of Molecular Genetics and the V.V. Zakusov Institute of Pharmacology developed Selank collaboratively, and Russian authorities approved it in 2009 as a nasal spray for generalized anxiety disorder and neurasthenia.

Unlike Semax, which primarily targets neurotrophic pathways, Selank's anxiolytic properties stem from modulation of the GABAergic system. Research published in PMC shows that Selank administration increases the expression of genes encoding GABA-A receptor subunits in the hippocampus and prefrontal cortex. The peptide does not directly bind GABA-A receptors like benzodiazepines do. Instead, it enhances receptor sensitivity to endogenous GABA.

Selank also inhibits enkephalin-degrading enzymes, specifically aminopeptidase N (APN) and dipeptidyl peptidase IV (DPP-IV). This inhibition raises circulating levels of leucine-enkephalin and methionine-enkephalin, endogenous opioid peptides with mood-regulating properties.

Gene expression studies found Selank affects four specific genes: Drd1a, Drd2, Slc6a13, and Ptgs2. These alterations influence neurotransmission pathways relevant to both anxiety and cognition.

How Are These Peptides Used Clinically in Russia?

Semax Indications

Russian physicians prescribe Semax for two primary indications:

Acute ischemic stroke: A 1% nasal spray administered during the acute period of hemispheric ischemic stroke. A study of 30 patients found that adding Semax to standard intensive therapy increased the rate of neurological recovery, particularly for motor function deficits.
Cognitive impairment: Used as a nootropic agent in patients with cerebrovascular insufficiency or post-stroke cognitive decline.

A larger study of 110 patients examined Semax's effects on stroke rehabilitation. The standard regimen consisted of two 10-day courses at 6,000 mcg/day intranasal, separated by a 20-day interval. Results showed elevated plasma BDNF levels that correlated with improved motor performance and Barthel index scores.

Selank Indications

Selank is prescribed in Russia for:

Generalized anxiety disorder: Clinical trials demonstrated anxiolytic efficacy comparable to benzodiazepines without the sedation, cognitive impairment, tolerance development, or withdrawal effects associated with that drug class.
Neurasthenia: A diagnostic category still used in Russian and Chinese psychiatry that corresponds roughly to chronic fatigue with anxiety and cognitive complaints.

2024 research from the Institute of Molecular Genetics found Selank reduced anxiety scores by 41% in individuals undergoing alcohol withdrawal, with effects appearing within 48 hours and persisting for 6-8 weeks after a 21-day administration protocol.

What Does the BDNF Research Show?

BDNF occupies a central position in neuroscience research on memory and cognitive function. It supports neuronal survival, promotes synaptogenesis (new synaptic connection formation), and enables long-term potentiation, the electrophysiological process underlying memory consolidation.

Semax triggers BDNF upregulation through CREB (cAMP response element-binding protein) phosphorylation. This is the same transcription factor pathway activated by exercise, environmental enrichment, and antidepressant medications. The Alzheimer's Drug Discovery Foundation notes that Semax's neurotrophic mechanism "has more mechanistic evidence than almost any Western-marketed nootropic."

Research examining temporal dynamics found that after Semax administration, BDNF expression increased significantly across multiple brain regions: hippocampus, frontal cortex, and retina. The expression levels peaked at 90 minutes post-administration.

Selank also increases BDNF expression, though this appears secondary to its GABAergic effects. The 2024 alcohol withdrawal study found Selank elevated BDNF alongside its anxiolytic effects, suggesting the mechanisms may be interconnected.

Why BDNF Matters for Cognitive Health

BDNF levels decline with age, chronic stress, inadequate sleep, and certain metabolic conditions. This decline correlates with reduced cognitive performance and increased vulnerability to neurodegenerative processes. Pharmacological agents that elevate BDNF represent one theoretical approach to addressing age-related cognitive decline.

The limitation is that elevated BDNF in animal models does not automatically translate to cognitive benefits in humans. The research base on Semax suggests correlation between BDNF elevation and cognitive improvement, but establishing direct causation requires more rigorous study design.

What Does the Alzheimer's Research Show?

Recent studies have examined Semax's potential relevance to Alzheimer's disease pathology, with findings on both amyloid aggregation and cognitive function in disease models.

Copper Chelation and Amyloid-Beta

A 2022 study in ACS Chemical Neuroscience demonstrated that Semax forms extremely stable complexes with copper (Cu²⁺) ions, with a conditional dissociation constant of 1.3 × 10⁻¹⁵ M at physiological pH. This matters because copper-amyloid beta complexes are implicated in Alzheimer's pathology.

The amyloid-beta/Cu²⁺ complex has a dissociation constant only in the nanomolar range. Semax's far stronger copper binding allows it to strip copper away from amyloid-beta, theoretically preventing the metal-driven aggregation that produces toxic plaques.

A 2025 study in Bioinorganic Chemistry and Applications extended this research, finding that Semax significantly reduced reactive oxygen species (ROS) production by the amyloid-beta/Cu²⁺ complex. Copper-catalyzed ROS generation through Fenton-like reactions is considered a key contributor to neuronal damage in Alzheimer's disease.

Cognitive Effects in Mouse Models

The most significant recent finding appeared in a 2025 study published in Acta Naturae. Researchers tested Semax and a derivative in transgenic APPswe/PS1dE9/Blg mice, a standard Alzheimer's model that develops amyloid plaques and cognitive deficits.

Key findings:

Both Semax and its derivative improved cognitive function as measured by open field, novel object recognition, and Barnes maze tests
Histological examination showed reduced amyloid inclusions in the cortex and hippocampus
This represents the first demonstration of functional cognitive improvement in a dedicated Alzheimer's mouse model

The researchers suggest Semax "could be considered a potential adjuvant in therapeutic approaches for neurodegenerative diseases." However, mouse model results do not predict human efficacy. The gap between preclinical promise and clinical reality in Alzheimer's drug development has been particularly wide.

What Is the Current US Regulatory Status?

Neither Semax nor Selank is FDA-approved for any therapeutic indication in the United States. The regulatory landscape shifted significantly in April 2026 when the FDA removed both peptides (along with BPC-157, TB-500, and others) from the 503A Category 2 list.

Understanding the Category 2 Removal

Semax was placed on FDA's 503A Category 2 list on September 29, 2023, flagged for immunogenicity risk from potential aggregation and peptide-related impurities for certain administration routes. The April 2026 removal occurred because the underlying nominations were withdrawn.

This removal does not authorize compounding under Section 503A. As legal analysis from Lengea Law clarifies: "Removal of a bulk drug substance from Category 2 does not, on its own, authorize use of that substance in compounding or bring it within FDA's interim enforcement discretion policy."

The July 2026 PCAC Meeting

On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee will convene at FDA's White Oak Campus in Silver Spring, Maryland to discuss several peptides for potential inclusion on the 503A Bulks List.

Semax discussion is scheduled for Day 2 (July 24). The medical uses under FDA review are:

Cerebral ischemia
Migraine
Trigeminal neuralgia

The Committee's role is advisory. If PCAC recommends inclusion and FDA agrees, the agency will initiate rulemaking to formally add Semax to the 503A Bulks List.

Public Comment Deadlines

Comments received by July 9, 2026 will be provided to the Committee before the meeting
The docket (FDA-2025-N-6895) closes July 22, 2026
Late comments will not be considered

What Are the Differences in Administration Routes?

Semax has poor oral bioavailability due to peptide degradation in the gastrointestinal tract. Two routes dominate the research literature.

Intranasal Administration

The nasal spray route is preferred for CNS effects:

CNS bioavailability: 10-20%
Onset: 15-30 minutes
Mechanism: Olfactory nerve transport bypasses the blood-brain barrier
Typical dosing: 200-600 mcg per nostril, 1-2 times daily
Clinical dosing (Russia): 600 to 12,000 mcg/day depending on indication

Researchers have administered intranasal Semax safely at doses up to 12 mg/day for 10 consecutive days without notable adverse effects.

Subcutaneous Injection

Injectable Semax offers more predictable systemic absorption:

Systemic bioavailability: 85-92%
CNS penetration: Only 2-5%
Onset: 45-90 minutes
Typical dosing: 500-1,000 mcg once daily

For cognitive effects specifically, the intranasal route achieves approximately 5-10 times greater CNS exposure despite lower total systemic absorption.

Selank follows similar administration patterns, with 0.15% nasal drops as the standard formulation in Russian clinical use.

What About Enhanced Variants Like Adamax?

Adamax (N-Acetyl Semax Amidate) is a modified version of Semax designed to address the parent compound's pharmacokinetic limitations. The modifications include:

N-terminal acetyl group: Slows enzymatic degradation
C-terminal adamantane moiety: Improves bioavailability and extends half-life

According to research summaries, Adamax operates through dual melanocortin MC3/MC4 receptor activation, with preferential MC4 binding driving cognitive enhancement properties. The MC4 receptor system regulates neuroplasticity through BDNF transcription and dendritic spine density modulation.

The trade-off is clear: Adamax has a smaller user base, narrower research foundation, and less developed safety data than Semax. Anyone using Adamax operates in a more experimental space than with the parent peptide.

What Are the Known Side Effects?

Semax Safety Profile

Published side effect data on Semax is limited but generally favorable:

Common: Nasal irritation with intranasal use
Less common: Transient anxiety or restlessness (more likely at higher doses due to dopaminergic activity), nausea, mild blood pressure fluctuations
Potential concerns: Possible glycemic effects in diabetic patients; caution with SSRIs, MAOIs, antipsychotics, or stimulants due to serotonergic/dopaminergic activity

One trial reported that a single 1 mg intranasal dose in 16 healthy but fatigued individuals may have resulted in slightly elevated anxiety levels.

Selank Safety Profile

Selank demonstrates a remarkably clean safety profile:

Common: Mild nasal irritation, transient stinging, nasal dryness with repeated intranasal use
No serious adverse events documented in published clinical studies
No dependence formation in clinical observations
Non-toxic at 200-500 times therapeutic doses in animal studies
Unlike benzodiazepines, no sedation, tolerance, or withdrawal effects in comparative studies

Critical Limitations

Neither peptide has established long-term human safety data beyond clinical trial durations of 14-30 days. The absence of long-term studies makes it impossible to characterize chronic effects or cumulative toxicity.

How Does the Evidence Quality Compare to Western Standards?

Both peptides have substantial clinical histories in Russia but face legitimate questions about evidence quality by FDA and EMA standards.

Study Limitations

Sample sizes have typically been small
Many studies lack placebo controls or adequate blinding
Neither compound has undergone the Phase III trials Western regulators require
Most published research appears in Russian-language journals
Independent Western replication is limited

The Alzheimer's Drug Discovery Foundation notes the evidence quality is "difficult to assess by Western standards."

What the Evidence Does Show

Despite these limitations, certain findings are consistent across multiple studies:

BDNF upregulation is well-documented in both animal and human studies
Semax's stroke benefits have been observed in several patient cohorts
Selank's anxiolytic effects have been replicated in comparative studies against benzodiazepines
Safety profiles appear favorable across all available data

The question is not whether these peptides have biological effects. The question is whether those effects meet the evidentiary thresholds that Western regulators require for therapeutic approval.

Key Takeaways

Semax and Selank are synthetic nootropic peptides approved in Russia for stroke recovery, cognitive impairment, and anxiety disorders
Both upregulate BDNF, the neurotrophic factor most associated with memory and learning
Semax will be reviewed at the FDA's July 2026 PCAC meeting for cerebral ischemia, migraine, and trigeminal neuralgia indications
Recent 2025 research shows Semax improved cognitive function and reduced amyloid plaques in Alzheimer's mouse models
Neither peptide is FDA-approved, and removal from Category 2 does not authorize compounding
Russian clinical data is substantial but does not meet Western Phase III standards
Side effects are generally mild, but long-term safety data is lacking

Frequently Asked Questions

Is Semax FDA-approved?

No. Semax is not FDA-approved for any therapeutic indication in the United States. It will be discussed at the July 2026 Pharmacy Compounding Advisory Committee meeting for potential inclusion on the 503A Bulks List, but even a positive recommendation does not constitute approval. The FDA would need to complete rulemaking before 503A compounding becomes permitted.

How do Semax and Selank differ?

Semax primarily targets neurotrophic pathways through BDNF upregulation and is prescribed in Russia for stroke recovery and cognitive enhancement. Selank primarily modulates the GABAergic system and is prescribed in Russia for anxiety disorders. Semax tends to have mild stimulating effects, while Selank produces calming effects without sedation.

What dosages are used in research studies?

Intranasal Semax dosing in clinical research ranges from 600 to 12,000 mcg/day depending on indication, typically administered over 10-30 day courses. Selank is typically administered as 0.15% nasal drops. These are research and clinical dosages from Russian medical practice; no standardized protocols exist for US clinical use.

Can these peptides be legally obtained in the US?

Both peptides exist in regulatory gray areas. They are not scheduled substances and can be sold as research chemicals. However, marketing them for human therapeutic use would violate FDA regulations. Compounding pharmacies cannot include them in preparations under current FDA guidance. The July 2026 PCAC meeting may change the regulatory landscape for Semax specifically.

Is there ongoing US clinical research?

No US clinical trials are currently registered on ClinicalTrials.gov for either Semax or Selank. All human clinical data originates from Russian and Eastern European research programs.

Conclusion

Semax and Selank represent a category of nootropic peptides with legitimate biological mechanisms and substantial clinical history outside Western medicine. The BDNF upregulation pathway is well-characterized, and Russian clinical data shows consistent effects on stroke recovery and anxiety reduction.

The regulatory gap between Russian approval and FDA recognition creates uncertainty for researchers and clinicians interested in these compounds. The July 2026 PCAC meeting will provide the first formal FDA evaluation of Semax for specific therapeutic indications, potentially opening a pathway to legitimate clinical access.

Until then, both peptides remain research compounds without approved therapeutic applications in the United States. The 2025 Alzheimer's mouse model data is promising but preliminary. Individuals considering these peptides should understand both the mechanistic rationale supporting their use and the evidentiary limitations that keep them outside FDA-approved medicine.

This content is for informational purposes only and does not constitute medical advice. Consult a healthcare provider before using any peptides or supplements.

Sources

Clinical TrialsFDA RegulationPCAC MeetingSemaxSelankNootropicsCognitive PeptidesBDNFAlzheimer's ResearchNeuroprotectionRussian Peptides

Written by

Peptide Portal Research

Editorial Team

Our research team combines expertise in biochemistry, pharmacology, and clinical research to deliver evidence-based content on peptide science.

PhD BiochemistryClinical Research

Last updated May 10, 2026